SGLT2 inhibitors – looking beyond glucose-lowering in diabetes | Cochrane UK
Forxiga (dapagliflozin) for Treatment of Type 2 Diabetes - Clinical Trials Arena
Visual Abstract | DAPA-HF - American College of Cardiology
DAPA ACT HF-TIMI 68 – TIMI STUDY GROUP
Dapagliflozin in Real World - ppt download
The role of dapagliflozin in the management of heart failure | TCRM
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial - ScienceDirect
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Diabetes & Endocrinology
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions - ScienceDirect
Figure 1 from Efficacy and safety of Dapagliflozin vs. Canagliflozin in addition to metformin for treatment of type 2 diabetes, a randomized, double-blind, non-inferiority clinical trial | Semantic Scholar
Ongoing Clinical Trials Assessing Dapagliflozin in Patients with Heart... | Download Scientific Diagram
Selected Clinical Trials of SGLT2 inhibitors in CVD ... | GrepMed
View of Dapagliflozin: Clinical practice compared with pre-registration trial data | British Journal of Diabetes
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function - Kidney International
JFP - Diabetes Volume 68, No. 01
ABCD - nationwide dapagliflozin audit
Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis | American Society of Nephrology
SGLT2 inhibitor reduces CV death and worsening HF events in HFrEF patients - PACE-CME
Efficacy results of randomized clinical trials with dapagliflozin... | Download Table
Efficacy data summary from the main phase 3 clinical trials of... | Download Table
Dapagliflozin helps reduce HbA1c and body weight in patients with type 2 diabetes as part of triple combination therapy: a subanalysis of four clinical studies - Virtual Meeting | EASD
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy - Kidney International
Outcomes in clinical trials compared with real-world data in patients... | Download Table
Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists - ScienceDirect
Safety data summary from the main phase 3 clinical trials of... | Download Table
